Valuation: Daré Bioscience, Inc.

Market Cap 12.57M 11.28M 10.3M 9.41M 17.75M 1.18B 18.29M 124M 49.52M 630M 47.17M 46.16M 1.99B P/E 2026 *
-0.88x
P/E 2027 * -1.25x
Enterprise Value 12.57M 11.28M 10.3M 9.41M 17.75M 1.18B 18.29M 124M 49.52M 630M 47.17M 46.16M 1.99B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 1.7x
Free-Float
88.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Daré Bioscience, Inc.

1 day+2.40%
1 week-8.66%
Current month-8.66%
1 month-19.11%
3 months-54.36%
6 months-78.04%
Current year-66.89%
1 week 0.61
Extreme 0.61
0.74
1 month 0.61
Extreme 0.61
0.79
Current year 0.61
Extreme 0.61
3.78
1 year 0.61
Extreme 0.61
3.78
3 years 0.61
Extreme 0.61
9.19
5 years 0.61
Extreme 0.61
30.12
10 years 0.61
Extreme 0.61
79.47
Manager TitleAgeSince
Chief Executive Officer 59 2017-06-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 71 2014-09-30
Chairman 78 2019-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

30,805 0.2056%
6/30/26 Free

Director

26,540 0.1772%
6/30/26 Free

Director

23,696 0.1582%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%-8.66%-65.08%-84.79% 12.57M
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.16%-2.25%+30.05%+60.62% 417.98B
Weighted average by Cap. -0.04%-1.96%+42.71%+88.11%

Financials

2026 *2027 *
Net sales 2.75M 2.47M 2.26M 2.06M 3.88M 258M 4M 27.21M 10.84M 138M 10.33M 10.1M 436M 7.4M 6.64M 6.06M 5.54M 10.45M 695M 10.77M 73.17M 29.15M 371M 27.77M 27.17M 1.17B
Net income -11.76M -10.55M -9.64M -8.8M -16.61M -1.1B -17.12M -116M -46.35M -589M -44.15M -43.2M -1.86B -10.05M -9.01M -8.24M -7.52M -14.19M -943M -14.62M -99.37M -39.58M -503M -37.71M -36.9M -1.59B
Net Debt - -
Projected Income Statement - Annual - Daré Bioscience, Inc.
Logo Daré Bioscience, Inc.
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Employees
23
Date Price Change Volume
26-11-06 US$0.6390 +2.40% 53,087
26-11-05 US$0.6240 -5.73% 146,642
26-11-04 US$0.6619 +1.83% 228,388
26-11-03 US$0.6500 -0.76% 138,938
26-11-02 US$0.6550 -6.38% 206,413
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Daré Bioscience, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6390USD
Average target price
6.333USD
Spread / Average Target
+891.13%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Daré Bioscience, Inc.
  1. Stock Market
  2. Stocks
  3. DARE Stock